Associate Professor David Woldbye
Department of Neuroscience
Mærsk Building, room 07-5-46
Phone: +45 4015 6389
The Woldbye lab has been studying the role of neuropeptide Y (NPY) and other neuropeptides in rodent behavioural and CNS disease models over the past 20 years.
The Woldbye lab has been studying the role of neuropeptide Y (NPY) and other neuropeptides in rodent behavioural and CNS disease models over the past 20 years. In recent years, the main focus has been very translational, aiming to develop viral vector-mediated gene therapeutic techniques as novel treatments for CNS disorders.
The present key goals of the lab include
i) exploration of NPY gene therapy for epilepsy in humans and dogs. In close collaboration with Prof M Kokaia (Lund Univ, Epilepsy Center), medical doctors at RH (e.g. Lars Pinborg), and CombiGene AB and daughter company Panion (Woldbye is co-founder of these companies), rodent epilepsy studies are conducted to establish efficacy and potential side effects to pave the way for the first clinical testing of gene therapy for epilepsy in humans and dogs;
ii) exploration of gene therapy for CNS neurodegenerative diseases. Based on a series of US-patented NPY-like peptides (by Woldbye/UCPH) neuroprotective treatments are being explored in rodent models and in cell cultures as potential therapy for Parkinson’s disease and dementias, as well as retinal diseases (NOVO pre-seed grant);
iii) explore mechanisms and potential treatments in mouse models of ADHD/visual attention using opto- and chemogenetics. Based on UCPH-supported major grant, in close collaboration with the Gether group, other research groups, and psychologists and psychiatrists at the UCPH, the Woldbye group studies the role of dopamine and noradrenalin projections in regulating visual attention using opto- and chemogenetics employing various behavioural mouse models.
Inventor on two patents (US 08901094, US 2016/0060320 A1) and two patent applications (WO2009112033-A1, EPA16164686.4).